An inhibitor of the enzymatic conversion of fructose-lysine into fructose-lysine-3-phosphate for use in the prevention or treatment of a condition selected from diabetic complications, hypertension, stroke, neurodegenerative disorders, circulatory disease, atherosclerosis, osteoarthritis, effects debilitating aging, or cataracts； wherein said condition is caused by the effects of 3-deoxyglucosone (3DG) in a patient, said 3DG being produced by the enzymatic conversion of fructose-lysine into fructose-lysine-3-phosphate: where the inhibitor has the formula: * * Formula ** in which X is -NR'- or -O-, R 'being selected from the group consisting of H, and straight or branched chain (C1-C4) alkyl group and an aryl group (C6-C10) ) or unsubstituted or substituted aralkyl group (C7-C10)； R is H or a lysine residue； said substituents being selected from aryl group (C6-C10) or aralkyl group (C7-C10) from the group consisting of H, (C1-C6) alkyl, halogen, CF3, CN, NO2 and -O-C1-C6 alkyl )； R1 is a polyol moiety having 1 to 4 linear carbon atoms, Y is any of a carbonyl moiety ** Formula ** or a hydroxymethylene moiety ** Formula ** Z is selected from the group consisting of -H , -OH, -O- (C1-C6) alkyl, -halogen -CF3, -CN, -COOH and -SO3H2, and the pharmaceutically acceptable isomers and salts of said compound.Un inhibidor de la conversión enzimática de fructosa-lisina en fructosa-lisina-3-fosfato para uso en la prevención o el tratamiento de una afección seleccionada entre complicaciones diabéticas, hipertensión, ictus, trastornos neurodegenerativos, enfermedad circulatoria, aterosclerosis, osteoartritis, los efectos debilitantes del envejecimiento, o cataratas； en donde dicha afección está causada por los efectos de la 3-desoxiglucosona (3DG) en un paciente, produciéndose dicha 3DG por la conversión enzimática de fructosa-lisina en fructosa-lisina-3-fosfato: en donde el inhibidor tiene la fórmula:**Fórmula** en la que X es -NR'- u -O-, seleccionándose R' entre el grupo que con
